GlaxoSmithKline Announces Approval and Availability of Avandaryl

GlaxoSmithKline announced the availability of Avandaryl (rosiglitazone maleate and glimepiride), a new fixed-dose combination product for type 2 diabetes.

“Recently approved by the U.S. Food and Drug Administration, Avandaryl is the first and only tablet to combine a thiazolidinedione [Avandia], with a sulfonylurea [Amaryl], to help improve blood sugar control,” says GlaxoSmithKline. “As an adjunct to diet and exercise, Avandaryl is indicated to improve blood sugar control in patients with type 2 diabetes who are already treated with a combination of [Avandia] and sulfonylurea, or who are not adequately controlled on a sulfonylurea alone, or for those patients who have initially responded to [Avandia] alone and require additional blood sugar control.”

Avandaryl is available in three tablet strengths: 4 mg/1 mg, 4 mg/2 mg and 4 mg/4 mg.

For more information about Avandaryl, log on to or call (888) 825-5249.

Leave a Reply

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.